ROSUVASTATIN 20mg. IP + FENOFIBRATE 160mg. IP

A combination therapy used to lower bad cholesterol (LDL, VLDL) and triglycerides while increasing good cholesterol (HDL). Provides dual action by controlling cholesterol and triglycerides in one tablet. (Paul N Durrington, 2004) A valuable treatment option for diabetic patients with high cholesterol and triglycerides. (Paul N Durrington, 2004) Reduces the risk of cardiovascular events in patients with hypertension and dyslipidemia. (Sungjae Lee, 2021) A beneficial option for managing multiple lipid abnormalities, including elevated LDL-C and triglycerides. (Eli M Roth, 2010) A safe and effective therapeutic approach for managing patients with mixed dyslipidemia. (Ajoy Tiwari, 2021) More efficacious than rosuvastatin alone in patients with mixed dyslipidemia. (Ajoy Tiwari, 2021) Significantly improves triglycerides, HDL-C, non-HDL-C, apolipoprotein B, and high-sensitivity C-reactive protein compared with simvastatin monotherapy. (Ajoy Tiwari, 2021) A safe option for treating challenging cases of mixed dyslipidemia. (Ajoy Tiwari, 2021)